Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Technology Insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer

Abstract

During the past decade, several high-throughput analytical methods have been developed, and most of these are being explored as potential diagnostic tools. Gene expression profiling with DNA microarrays or with multiplex polymerase chain reaction are the methods closest to being of clinical use. Prediction of clinically meaningful response to particular chemotherapy regimens or drugs remains a persistent challenge. There are established clinical and histopathologic predictors of prognosis for breast cancer, but there is no test to assist in selecting the optimal chemotherapy regimen for patients. Here we review recent advances in the application of gene expression profiling to chemotherapy response prediction.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Development strategies for pharmacogenomic predictors.

Similar content being viewed by others

References

  1. Early Breast Cancer Trialists' Collaborative Group (1999) Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352: 930–942

  2. Fisher B et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672–2685

    Article  CAS  Google Scholar 

  3. Rouzier R et al. (2002) Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20: 1304–1310

    Article  Google Scholar 

  4. Buchholz TA et al. (2002) Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 53: 880–888

    Article  Google Scholar 

  5. Chen AM et al. (2004) Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. J Clin Oncol 22: 2303–2312

    Article  Google Scholar 

  6. Bonadonna G et al. (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93–100

    Article  CAS  Google Scholar 

  7. Kaufmann M et al. (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21: 2600–2608

    Article  Google Scholar 

  8. Smith IC et al. (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456–1466

    Article  CAS  Google Scholar 

  9. National Comprehensive Cancer Network, Breast Cancer Practice Guidelines (http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf)

  10. Goldhirsch A et al. (2003) Meeting highlights: updated international expert consensus panel on the primary therapy of early breast cancer. J Clin Oncol 21: 1–9

    Article  Google Scholar 

  11. Abu-Farsakh H et al. (1995) Pathologic predictors of tumor response to preoperative chemotherapy in locally advanced breast carcinoma. Breast J 1: 96–101

    Article  Google Scholar 

  12. Colleoni M et al. (2000) Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11: 1057–1059

    Article  CAS  Google Scholar 

  13. Kuerer HM et al. (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460–469

    Article  CAS  Google Scholar 

  14. Bast RC Jr et al. (2001) 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865–187875

    Article  Google Scholar 

  15. Chang J et al. (1999) Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058–3063

    Article  CAS  Google Scholar 

  16. Ellis P et al. (1998) Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 16: 107–114

    Article  CAS  Google Scholar 

  17. Zhang F et al. (2003) Correlation between HER2 expression and response to neoadjuvant FAC chemotherapy in breast cancer. Cancer 97: 1758–1765

    Article  CAS  Google Scholar 

  18. Rozan S et al. (1998) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79: 27–33

    Article  CAS  Google Scholar 

  19. Hortobagyi GN et al. In 2002 ASCO Annual Meeting Summaries; 2002 May 18-21; Orlando, FL. ASCO

  20. Burns TF et al. (2003) Cell death signaling in malignancy. Cancer Treat Res 115: 319–343

    Article  CAS  Google Scholar 

  21. Ramaswamy S and Golub TR (2002) DNA microarrays in clinical oncology. J Clin Oncol 20: 1932–1941

    Article  CAS  Google Scholar 

  22. de Bolle X and Bayliss CD (2003) Gene expression technology. Methods Mol Med 71: 135–146

    PubMed  Google Scholar 

  23. Walker SJ et al. (2003) Semiquantitative real-time PCR for analysis of mRNA levels. Methods Mol Med 79: 211–227

    CAS  PubMed  Google Scholar 

  24. Rajeevan MS et al. (2001) Validation of array-based gene expression profiles by real-time (kinetic) RT–PCR. J Mol Diagn 3: 26–31

    Article  CAS  Google Scholar 

  25. Baunoch D et al.: Microarray analysis of formalin fixed paraffin-embedded tissue: the development of a gene expression staging system for breast carcinoma. In San Antonio Breast Cancer Symposium; 2003 December 3–6; San Antonio, TX. Edited by Lippman ME. Kluwer Academic

  26. Paik S et al.: Multi-gene RT–PCR assay for predicting recurrence in node negative breast cancer patients—NSABP studies B-20 and B-14. In San Antonio Breast Cancer Symposium; 2003 December 3–6; San Antonio, TX. Edited by Lippman ME. Kluwer Academic

  27. Simon R et al. (2003) Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95: 14–18

    Article  CAS  Google Scholar 

  28. Cui X and Churchill GA (2003) Statistical tests for differential expression in cDNA microarray experiments. Genome Biol 4: 210

  29. Simon R et al. (2002) Design of studies using DNA microarrays. Genet Epidemiol 23: 21–36

    Article  Google Scholar 

  30. Sotiriou C et al. (2002) Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4: R3

    Article  Google Scholar 

  31. Assersohn L et al. (2002) The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin Cancer Res 8: 794–801

    CAS  PubMed  Google Scholar 

  32. Pusztai L et al. (2003) Gene expression profiles obtained from single passage fine needle aspirations (FNA) of breast cancer reliably identify prognostic/predictive markers such as estrogen (ER) and HER-2 receptor status and reveal large scale molecular differences between ER-negative and ER-positive tumors. Clin Cancer Res 9: 2406–2415

    CAS  PubMed  Google Scholar 

  33. Ellis M et al. (2002) Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res 8: 1155–1166

    CAS  PubMed  Google Scholar 

  34. Symmans WF et al. (2003) Fine needle aspiration and core needle biopsy samples of breast cancer provide similar total RNA yield, but different stromal gene expression profiles cancer. Cancer 97: 2960–2971

    Article  CAS  Google Scholar 

  35. Radmacher MD et al. (2002) A paradigm for class prediction using gene expression profiles. J Comput Biol 9: 505–511

    Article  CAS  Google Scholar 

  36. Chang JC et al. (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362–369

    Article  CAS  Google Scholar 

  37. Ayers M et al. (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. J Clin Oncol 22: 2284–2293

    Article  CAS  Google Scholar 

  38. Gianni L : In Proceedings of 40th Annual American Society of Clinical Oncology Meeting; 2004 June 5–8; New Orleans. Edited by Grunberg SN. ASCO

  39. yoshimoto M : In Proceedings of 40th Annual American Society of Clinical Oncology Meeting; 2004 June 5–8; New Orleans. Edited by Grunberg SN. ASCO

  40. Hannemann J : In Proceedings of 40th Annual American Society of Clinical Oncology Meeting; 2004 June 5–8; New Orleans. Edited by Grunberg SN. ASCO

  41. Buchholz TA et al. (2002) Global gene expression changes during neoadjuvant chemotherapy of human breast cancer. Cancer J 8: 461–468

    Article  Google Scholar 

  42. Mukherjee S et al. (2003) Estimating dataset size requirements for classifying DNA microarray data. J Comput Biol 10: 119–42

    Article  CAS  Google Scholar 

  43. Chakravarthy B and Pietenpol JA (2003) Combined modality management of breast cancer: development of predictive markers through proteomics. Semin Oncol 30 (4 Suppl 9): 23–36

    Article  CAS  Google Scholar 

  44. Fusaro VA and Stone JH (2003) Mass spectrometry-based proteomics and analyses of serum: a primer for the clinical investigator. Clin Exp Rheumatol 21 (6 Suppl 32): S3–S14

    CAS  PubMed  Google Scholar 

  45. Pusztai L et al. (2004) Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100: 1814–1822

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lajos Pusztai.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pusztai, L., Gianni, L. Technology Insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer. Nat Rev Clin Oncol 1, 44–50 (2004). https://doi.org/10.1038/ncponc0025

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0025

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing